March 2, 2015
Otsuka Pharmaceutical said on February 27 that its Canadian affiliate Otsuka Canada Pharmaceutical Inc. has received regulatory approval for its autosomal dominant polycystic kidney disease (ADPKD) treatment Jinarc (tolvaptan; brand name in Japan: Samsca) from the Canadian authorities Health Canada...read more